Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Japan Sees Delay in Pilot-Based Revenue Assurance System for Antibiotics, Criteria Still Up in Air
August 9, 2023
- MHLW Panel OKs Online Sales of Behind-the-Counter Drugs, but with Pharmacists’ Online Supervision
August 9, 2023
- Approve 16 Pediatric Cancer Meds as Exceptional Step Beyond Law, Oncologist Urges
August 8, 2023
- Novartis’ siRNA Dyslipidemia Therapy and More Up for Panel Review on August 21
August 8, 2023
- MHLW Panel to Review Alzheimer’s Med Lecanemab on August 21
August 8, 2023
- Japan Adopts New Evaluation Method for Nitrosamine Impurities Risks
August 7, 2023
- Japan’s Healthcare Spending Up 11.0% in FY2021: IPSS Report
August 7, 2023
- Despite Increase in Reviewers, Japan Faces Backlog of Over 4,000 Health Damage Claims for COVID Jabs
August 4, 2023
- With Generics Now in Common Use, It’s Time for Debate on LLP Copay: Payers
August 4, 2023
- Japan to Set Up New Forum on Dementia Measures: PM
August 4, 2023
- 30% of Eligible Population Unaware of HPV Vaccine: Survey
August 4, 2023
- Payers Want Phase-Out of Medical Fee Premiums for Generic Use; HCPs Eye Change in Entry Pricing
August 3, 2023
- Chuikyo OKs Plan to Move Back Medical Fee Revisions to June from FY2024; Drug Price Updates to Remain in April
August 3, 2023
- Industry Calls for Excluding Orphan Drugs from Cost-Effectiveness Assessment
August 3, 2023
- Chuikyo Reps Criticize Manufacturers’ Price Cuts after Unprofitability Re-Pricing
August 3, 2023
- Relief Claims OK’ed for 38 More Deaths after COVID Vaccination
August 2, 2023
- Generics Panel Initiates Debate toward Proposing Stable Supply Measures, Interim Report Slated for October
August 1, 2023
- Pharma Regulation Panel to Discuss Need for PI Japanese Data on Aug. 7
August 1, 2023
- Perjeta/Herceptin SC Combo, 1st Stelara, G-Lasta Biosimilars in Line for Japan Approval
August 1, 2023
- Japan Panel Shelves Decision on Shionogi’s COVID Vaccine over Efficacy Data
August 1, 2023
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…